A preclinical study co-led by Cedars-Sinai Health Sciences University identified UBE2N as a potential therapeutic target; restoring its levels in laboratory mice reduced fat accumulation, inflammation, and scarring, suggesting its potential to prevent MASLD from advancing to MASH.